Top California Pharmaceutical Companies (369)
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.
Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.
Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Newer and acquired medicines grew 18% operationally in Q2 2026, while revenue excluding Comirnaty and Paxlovid rose 5% operationally in the same period. Excluding COVID products, 2025 revenue also increased 6% operationally, supported by growth in products such as Eliquis and Padcev.
Cost & Operational Efficiency: Management is pursuing additional savings to improve operational efficiency and support profitability. These cost-control efforts are intended to help the business transition away from pandemic-driven sales while supporting margins.
Innovation-Driven Growth: Investment in future growth includes $10.4 billion in internal R&D during 2025 and ongoing development in oncology and obesity. A broad pipeline and recent acquisitions are intended to offset declining COVID-19 sales and patent expirations if programs succeed.
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California,...
Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale
Resilience (resilience.com).'s Top Stability & Growth Strengths
Investor Backing & Capital Strength: The company is described as well-funded, with multiple sizable financing events including up to $825M in long-term financing to accelerate its CDMO strategy and prior large equity rounds. Public-sector funding and government-backed initiatives are also cited as signals of confidence in its role in domestic manufacturing and supply-chain resilience.
Strategic Partnerships: The business has landed recognizable relationships such as an AstraZeneca fill/finish deal and earlier work with Takeda, which help validate its capabilities and quality expectations. Additional collaborations with research institutions are positioned as strengthening its advanced-therapy offering.
Future-Ready Strategy: The operating model is oriented toward complex modalities (biologics, vaccines, nucleic acids, cell and gene therapy) with drug substance and fill/finish capabilities, positioning it toward segments expected to remain strategically important. The post-2025 pivot toward a smaller set of “go-forward” hubs is framed as a refocus on higher-demand areas like sterile drug product and selected biologics/cell-therapy capabilities.
Varda Space Industries was founded in 2020 with the goal of manufacturing products in space to benefit life on Earth. Co-founders Will Bruey and Delian Asparouhov imagined a world where space could be leveraged not only for storytelling and awe, but for its economic benefits. Varda was created as a platform for in-space manufacturing, with a range of real-life, on-Earth...
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids* , as well as...
Neurocrine Biosciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Reported results indicate category leadership in VMAT2 inhibitors by sales, with INGREZZA posting $2.3B in 2024 and guided to $2.5–$2.55B for 2025, outpacing Austedo’s outlook. Feedback suggests broader Medicare coverage and long‑term safety data help defend the TD/HD chorea franchise near term.
Diversified Revenue Streams: Reported FDA approval and early uptake of CRENESSITY create a new, defensible revenue stream in CAH alongside INGREZZA. Launch metrics referencing patient starts, payer coverage, and sequential sales growth through 2025 indicate increasing contribution.
Strong Revenue Growth: Reported financials show annual revenue grew about 25% in 2024 and total net product sales rose 28% year over year in Q3 2025. Momentum reflects sustained INGREZZA volume growth with incremental contribution from CRENESSITY.
Vanderbilt University Medical Center is a leading academic health system in the Southeast dedicated to providing patient care, conducting medical research, and training the next generation of health professionals.
Vanderbilt University Medical Center's Top Stability & Growth Strengths
Market Expansion: Feedback suggests the system is scaling its regional footprint through acquisitions and new community sites, moving toward an integrated regional model.
Product Line Growth: Feedback suggests specialized clinical services are expanding, with milestones such as record organ transplant volumes indicating capacity growth in complex care.
Innovation-Driven Growth: Feedback suggests the organization is integrating AI and research partnerships to improve clinical efficiency and scale without proportional workforce increases.
Living Goods is a non-profit organization that empowers community health workers with digital tools to deliver lifesaving primary healthcare door-to-door. By partnering with governments and leveraging smart mobile technology, they provide essential medicines and training to underserved families, specifically focusing on reducing child mortality and improving health outcomes across Africa through an innovative retail-inspired distribution model.
Cellbyte builds AI agents for pharmaceutical drug launches. By automating repetitive workflows on top of our robust data foundation, we help pharma companies bring life-changing treatments to patients faster than ever before. We are backed by amazing investors, such as Y Combinator or Frontline VC.
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to...
Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients. Pliant’s...
NKGen Biotech is a clinical-stage biotechnology company developing and commercializing natural killer (NK) cell therapies using its proprietary SNK platform. Its autologous, allogeneic, and CAR-NK candidates are intended to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, as well as cancers. The company’s platform uses activated NK cells, which it aims to bring to patients through clinical development and eventual commercialization.
There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.
Otsuka America Pharmaceutical's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures indicate double-digit growth at the parent level with North America identified as the largest and expanding region. Management attributes momentum to U.S.-marketed medicines such as REXULTI, ABILIFY MAINTENA, and JYNARQUE powering the pharmaceutical segment.
Strong Market Position & Advantage: The company is repeatedly portrayed as a leader in mental health and nephrology, supported by first-in-class and category-defining therapies. Flagship assets like aripiprazole long-acting injectables, REXULTI’s Alzheimer’s agitation indication, and JYNARQUE underpin durable positioning in core niches.
Innovation-Driven Growth: Multiple approvals, priority reviews, and acquisitions underscore an active pipeline across CNS and renal diseases. Examples include FDA priority review for centanafadine, accelerated approval for sibeprenlimab, digital therapeutic launches, and targeted deals to strengthen U.S. capabilities.
Best Formulations is a California-based contract manufacturer specializing in the development and commercialization of nutraceuticals, pharmaceutical products, and dietary supplements. Founded in 1984, the company is one of the largest producers of plant-based softgels in the United States. Now part of Sirio Pharma, it provides turnkey solutions, including proprietary formulations and vertically integrated manufacturing and packaging for the health and...
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and...
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's...
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism...
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the...

































